Appointment sheet
Adenocarcinoma of the lung
Prepared with OnCo (onco.cc/prep/lung-adenocarcinoma/). Orientation, not medical advice; your team knows your case.
My details
Name
Date of appointment
Hospital and clinician
Who is coming with me
What I know, what is unclear, changes to discuss
Saved in this browserWhat I know so far
What is unclear to me
Changes since last time
My questions
11 on the sheetNewly diagnosed
- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example TTF-1 and napsin A on immunohistochemistry, EGFR, ALK, ROS1, BRAF, MET exon 14, RET, KRAS G12C, HER2 and NTRK testing before first-line therapy, PD-L1 tumour proportion score, Predominant pattern and WHO 2021 grade; spread through air spaces), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
Advanced, driver-negative
- 5.For my situation (advanced, driver-negative), which of the standard options do you recommend and why?
- 6.Am I a candidate for Pembrolizumab, Pemetrexed, Carboplatin or related drugs, and what side effects should I expect?
- 7.How do the results of TROPION-Lung01 apply to someone like me?
Advanced with a driver
- 8.For my situation (advanced with a driver), which of the standard options do you recommend and why?
Early stage
- 9.For my situation (early stage), which of the standard options do you recommend and why?
Any stage
- 10.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 11.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
The words I may hear
- Lobectomy: Removing one lobe of the lung (the right lung has three, the left two).
Tests and results to bring
Biomarker results to ask for: TTF-1 and napsin A on immunohistochemistry, EGFR, ALK, ROS1, BRAF, MET exon 14, RET, KRAS G12C, HER2 and NTRK testing before first-line therapy, PD-L1 tumour proportion score, Predominant pattern and WHO 2021 grade; spread through air spaces.
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- Early stage: Treated as the parent's resectable and stage III pages describe; histology does not change the surgery. (Resectable stage I to III non-small-cell lung cancer, Unresectable stage III non-small-cell lung cancer, Lobectomy)
- Advanced, driver-negative: Pembrolizumab with platinum and pemetrexed (KEYNOTE-189), or the parent's PD-L1-high pathway when the score is 50 percent or more; datopotamab deruxtecan after chemotherapy (TROPION-Lung01). (Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin, TROPION-Lung01, PD-L1-high non-small-cell lung cancer without a driver mutation)
- Advanced with a driver: Treated on the parent's driver pages (EGFR, ALK, ROS1, RET, MET, KRAS G12C, HER2, NTRK, BRAF). (Non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, ALK-positive non-small-cell lung cancer, KRAS G12C-mutant non-small-cell lung cancer, MET exon 14 and MET-amplified non-small-cell lung cancer)
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.
Answers and next steps
Saved in this browserWhat I was told
Agreed next steps, dates and who to call